0.8909

3.87% -0.0359

After Hours: .91 0.0191 +2.14%

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $0.8909, with a volume of 1.17M. It is down -3.87% in the last 24 hours and up +30.44% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Previous Close:

$0.9268

Open:

$0.91

24h Volume:

1.17M

Relative Volume:

0.47

Market Cap:

$87.30M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+9.89%

1M Performance:

+30.44%

6M Performance:

-82.97%

1Y Performance:

-75.25%

1-Day Range:

$0.8523

$0.9181

1-Week Range:

$0.8163

$0.9352

52-Week Range:

$0.64

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	0.8909	90.81M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

Feb 06, 2026

Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews

Feb 06, 2026

Aug Summary: Does aTyr Pharma Inc have pricing powerJuly 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn

Feb 06, 2026

Feb 05, 2026

Market Outlook: Does aTyr Pharma Inc have pricing powerJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn

Feb 05, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (ATYR), Pfizer (PFE) and Bicycle Therapeutics (BCYC) - The Globe and Mail

Feb 05, 2026

Atyr Pharma CEO Shukla sells $3.6k in stock By Investing.com - Investing.com Nigeria

Feb 05, 2026

Atyr Pharma CEO Shukla sells $3.6k in stock - Investing.com UK

Feb 05, 2026

Atyr Pharma CFO Broadfoot sells $1.5k in stock By Investing.com - Investing.com South Africa

Feb 05, 2026

Atyr Pharma CFO Broadfoot sells $1.5k in stock - Investing.com

Feb 05, 2026

Feb 04, 2026

aTyr Pharma general counsel sells $1091 in stock By Investing.com - Investing.com UK

Feb 04, 2026

aTyr Pharma general counsel sells $1091 in stock - Investing.com

Feb 04, 2026

Feb 03, 2026

FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting - Investing.com Nigeria

Feb 03, 2026

aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ) - Seeking Alpha

Feb 03, 2026

Atyr Pharma announces scheduling of FDA type C meeting to discuss efzofitimod program in pulmonary sarcoidosis - marketscreener.com

Feb 03, 2026

aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod - GuruFocus

Feb 03, 2026

aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis - Quiver Quantitative

Feb 03, 2026

ATyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - marketscreener.com

Feb 03, 2026

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - GlobeNewswire

Feb 03, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Feb 03, 2026

Feb 02, 2026

Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat

Feb 02, 2026

Short Interest in aTyr Pharma, Inc. (NASDAQ:ATYR) Drops By 14.7% - MarketBeat

Feb 02, 2026

Jan 30, 2026

Aug Action: What is aTyr Pharma Inc.’s TAM (Total Addressable Market)2025 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn

Jan 30, 2026

Jan 29, 2026

Is aTyr Pharma Inc. stock forming a triangle patternJuly 2025 Catalysts & Safe Capital Preservation Plans - Mfd.ru

Jan 29, 2026

Jan 21, 2026

Is aTyr Pharma Inc backed by strong institutional buyingJuly 2025 WrapUp & Reliable Intraday Trade Plans - baoquankhu1.vn

Jan 21, 2026

Jan 20, 2026

Aug Update: Does aTyr Pharma Inc. have pricing powerMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn

Jan 20, 2026

Jan 19, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest - MarketBeat

Jan 19, 2026

Jan 17, 2026

Published on: 2026-01-18 01:23:30 - baoquankhu1.vn

Jan 17, 2026

Jan 14, 2026

Volume Recap: What drives aTyr Pharma Incs stock priceWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn

Jan 14, 2026

Jan 11, 2026

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Jan 11, 2026

Jan 09, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Jan 09, 2026

Jan 08, 2026

How aTyr Pharma Inc. stock benefits from tech adoptionMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru

Jan 08, 2026

Will aTyr Pharma Inc. stock outperform growth indexesTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru

Jan 08, 2026

Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 Summary & Long-Term Growth Plans - ulpravda.ru

Jan 08, 2026

Aug Chart Watch: How aTyr Pharma Inc. stock benefits from tech adoptionWeekly Stock Recap & Intraday High Probability Alerts - ulpravda.ru

Jan 08, 2026

Can aTyr Pharma Inc. (471A) stock sustain breakout momentumDay Trade & Safe Capital Allocation Plans - ulpravda.ru

Jan 08, 2026

Aug EndMonth: Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - ulpravda.ru

Jan 08, 2026

How strong is aTyr Pharma Inc. stock revenue growthPortfolio Return Report & Low Risk Investment Opportunities - ulpravda.ru

Jan 08, 2026